Literature DB >> 6522922

Pharmacokinetic disposition of cefonicid in patients with renal failure and receiving hemodialysis.

S L Barriere, J G Gambertoglio, D P Alexander, R J Stagg, J E Conte.   

Abstract

Cefonicid is a new cephalosporin with a spectrum of activity similar to that of cefamandole. The pharmacokinetic disposition of the drug was examined in patients with various degrees of renal dysfunction and who were receiving hemodialysis. After patients were given a 7.5 mg/kg dose as an iv infusion, multiple blood and urine samples were obtained at frequent intervals, and the samples were analyzed for cefonicid concentration. Five patients receiving hemodialysis received an additional dose before a dialysis period to assess removal of the drug. The half-life of cefonicid increased markedly with declining renal function (approximately 70 hr in anuric patients). Total clearance and renal clearance decreased linearly with decreases in creatinine clearance. Steady-state volume of distribution remained approximately the same (0.11 liter/kg) in all patients. Cefonicid dosage can be reduced in proportion to decreases in creatinine clearance from normal levels. A simple nomogram is provided.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6522922     DOI: 10.1093/clinids/6.supplement_4.s809

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  3 in total

Review 1.  Clinical pharmacokinetics of antibiotics in patients with impaired renal function.

Authors:  W L St Peter; K A Redic-Kill; C E Halstenson
Journal:  Clin Pharmacokinet       Date:  1992-03       Impact factor: 6.447

Review 2.  Cefonicid. A review of its antibacterial activity, pharmacological properties and therapeutic use.

Authors:  E Saltiel; R N Brogden
Journal:  Drugs       Date:  1986-09       Impact factor: 9.546

3.  Pharmacokinetics of cefonicid in patients with skin and skin structure infections.

Authors:  K L Heim-Duthoy; G L Peltier; D R Guay; G R Matzke
Journal:  Antimicrob Agents Chemother       Date:  1988-04       Impact factor: 5.191

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.